Clinical data | |
---|---|
Trade names | Plegridy, Plegridy Pen |
Other names | BIIB-017 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a614059 |
License data | |
Pregnancy category |
|
Routes of administration | Subcutaneous injection |
Drug class | Antineoplastic agent |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C913H1417N246O256PS7 [C2H4O]n |
Molar mass | 44000 g·mol−1 |
Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis. [4] [5]
The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site. [4] [5]
Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014. [6] [5]
In the United States, peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. [4]
In the European Union, peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults. [5]
Clinical data | |
---|---|
Trade names | Plegridy, Plegridy Pen |
Other names | BIIB-017 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a614059 |
License data | |
Pregnancy category |
|
Routes of administration | Subcutaneous injection |
Drug class | Antineoplastic agent |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C913H1417N246O256PS7 [C2H4O]n |
Molar mass | 44000 g·mol−1 |
Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis. [4] [5]
The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site. [4] [5]
Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014. [6] [5]
In the United States, peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. [4]
In the European Union, peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults. [5]